Hong Kong-listed innovative drug concept stocks fell collectively, with Zai Lab (09688.HK) down more than 11%, Hengrui Medicine (01276.HK), Ascletis Pharma (01672.HK), and Everest Medicines (01952.HK) down more than 5%, WuXi AppTec (02359.HK) down more than 4%, Innovent Biologics (01801.HK), WuXi Partners (02268.HK), and Hansoh Pharmaceutical (03692.HK) down more than 3%.

2025-09-04 10:31:58

WuXi AppTec

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Qualcomm (QCOM.O) CEO: Qualcomm needs more energy-efficient chips.
                            2025-09-06

                                    Jefferies: Raised Alibaba (BABA.N) price target from $150.00 to $165.00.
                            2025-09-01

                                    The statement showed that Alibaba and Bosch announced the deepening of their strategic partnership.
                            2025-09-02

                                    The value of projects signed at the 2025 Smart Expo exceeds 200 billion yuan
                            2025-09-05

                                    Challenger Gray, a US employment consulting firm, reports that pharmaceutical companies announced plans to lay off 19,112 employees in August, bringing the total to 22,433. This represents a 142% increase compared to the 9,254 layoffs reported in the same period last year. The industry is facing increasing competition from patent expirations and is refocusing on higher-margin products. Many companies are also implementing artificial intelligence, which is leading to restructuring and job losses.
                            2025-09-04